Knowledge about early treatment and prevention measures for Covid-19 in residents of the State of Pará-Brazil
DOI:
https://doi.org/10.33448/rsd-v10i12.20486Keywords:
Covid-19; Epidemiology; Public health; Drug treatment.Abstract
Since the beginning of the pandemic, several drugs have been studied as alternatives to treat COVID-19 infection. These include chloroquine, ivermectin, hydroxychloroquine and nitazoxanide. The present study sought to identify the knowledge and behavior about the use of drugs without scientific evidence in part of the population of the state of Pará, during the COVID-19 pandemic. The research adopted a descriptive and prospective approach, involving a questionnaire in an electronic form, to collect data from residents of the state. The results showed that the frequency of individuals who believed in early treatment and/or use of medication as prophylaxis was higher in residents of cities in the interior of the state and in older age groups, despite the contrary scientific findings. In the population studied, 9.9% of residents in other cities did not believe that vaccines were safe and effective, and 7.0% reported that only a few would be. The ideological orientation of a part of the population and anti-vaccination movements can partly explain the results presented. The inappropriate use of drugs for the early treatment and/or prophylactic use of COVID-19 is still a reality in the state of Pará, and public policies must be implemented to curb such use and increase actions that seek to raise awareness about the importance of vaccination and maintenance of scientifically proven prevention measures.
References
Axfors, C., Schmitt, A. M., Janiaud, P., van’t Hooft, J., Abd-Elsalam, S., Abdo, E. F., ... & Hemkens, L. G. (2021). Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nature communications, 12(1), 1-13.
Beltrão, R. P. L., Mouta, A. A. N., Silva, N. S., Oliveira, J. E. N., Beltrão, I. T., Beltrão, C. M. F., ... & da Silva, A. C. B. (2020). Perigo do movimento antivacina: análise epidemio-literária do movimento antivacinação no Brasil. Revista Eletrônica Acervo Saúde, 12(6), e3088-e3088.
Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., ... & Hullsiek, K. H. (2020). A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. New England Journal of Medicine, 383(6), 517-525.
Brasil, M. S. (2020a). Orientações do Ministério da Saúde para manuseio medicamentoso precoce de pacientes com diagnóstico da Covid-19. Ministério da Saúde.
Brasil, M. S. (2020b) Nota Informativa no 17/2020- SE/GAB/SE/MS. Orientações do Ministério da Saúde para manuseio medicamentoso precoce de pacientes com diagnóstico da Covid-19. [Web page] Retrivied from
http://antigo.saude.gov.br/images/pdf/2020/August/12/COVID-11ago2020-17h16.pdf.
Brasil. (2020b). Portaria MS/GM nº 188, de 3 de fevereiro de 2020. Declara Emergência em Saúde Pública de importância Nacional (ESPIN) em decorrência da Infecção Humana pelo novo Coronavírus (2019-nCoV). Diário Oficial da União.
Centers for Disease Control and Prevention (2020). Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) [Web page]. Retrivied from https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html.
Chaccour, C., Hammann, F., Ramón-García, S., & Rabinovich, N. R. (2020). Ivermectin and COVID-19: keeping rigor in times of urgency. The American journal of tropical medicine and hygiene, 102(6), 1156.
Gautret, P., Lagier, J. C., Parola, P., Meddeb, L., Mailhe, M., Doudier, B., ... & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents, 56(1), 105949.
Gostin, L. O. (2020). The great coronavirus pandemic of 2020—7 critical lessons. Jama, 324(18), 1816-1817.
Hongchao, P., Peto, R., Henao-Restrepo, A. M., Preziosi, M. P., Sathiyamoorthy, V., Karim, Q. A., ... & Manuel, O. (2020). Repurposed antiviral drugs for COVID-19: interim WHO solidarity trial results (Preprint).
International Committee on Taxonomy of Viruses (2011). Coronaviridae—Positive Sense, R. N. A. Viruses—Positive Sense RNA Viruses [Web page]. Retrivied from https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-rna-viruses-2011/w/posrna_viruses/222/coronaviridae.
Lima, C. H. (2021). História psicossocial das emergências humanitárias: Uma sistematização da resposta brasileira ao impacto da COVID-19 na saúde da população. Research, Society and Development, 10(8), e30610817275-e30610817275.
López-Medina, E., López, P., Hurtado, I. C., Dávalos, D. M., Ramirez, O., Martínez, E., ... & Caicedo, I. (2021). Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. Jama, 325(14), 1426-1435.
Mitjà, O., Corbacho-Monné, M., Ubals, M., Alemany, A., Suñer, C., Tebé, C., ... & Clotet, B. (2020). A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. New England Journal of Medicine.
RECOVERY Collaborative Group. (2020). Effect of hydroxychloroquine in hospitalized patients with Covid-19. New England Journal of Medicine, 383(21), 2030-2040.
Rocco, P. R., Silva, P. L., Cruz, F. F., Melo-Junior, M. A. C., Tierno, P. F., Moura, M. A., ... & e Silva, J. R. L. (2021). Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. European Respiratory Journal, 58(1).
Santos-Pinto, C. D. B., Miranda, E. S., & Osorio-de-Castro, C. G. S. (2021). O “kit-covid” e o Programa Farmácia Popular do Brasil. Cadernos de Saúde Pública, 37.
Secretaria de Estado de Saúde do Mato Grosso (2020). Veja a lista com as dez principais fake news sobre o coronavírus [Web page]. Retrivied from http://www.mt.gov.br/-/14066969-veja-a-lista-com-as-dez-principais-fake-news-sobre-o-coronavirus.
Secretaria de Estado da Saúde do Pará - SESPA (2020). Coronavírus [Web page]. Retrivied from http://www.saude.pa.gov.br/coronavirus.
Secretaria de Estado da Saúde do Pará - SESPA (2021a). Coronavírus [Web page]. Retrivied from http:// http://www.saude.pa.gov.br/vacinometro/.
Secretaria de Estado da Saúde do Pará - SESPA (2021b). Plano Paraense de Vacinação – PPV/COVID-19. 4º Edição. Retrivied from http://www.saude.pa.gov.br/coronavirus/nota-tecnica-covid/.
Singh, B., Ryan, H., Kredo, T., Chaplin, M., & Fletcher, T. (2020). Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19. The Cochrane database of systematic reviews, 2020(4).
World Health Organization (2021). Coronavirus Disease (COVID-19) [Web page]. Retrivied from: https://covid19.who.int/.
World Health Organization (2020). OMS declara emergência de saúde pública de importância internacional por surto de novo coronavírus [Web page]. Retrivied from https://www.paho.org/bra/index.php?option=com_content&view=article&id=6100:oms-declara-emergencia-de-saude-publica-de-importancia-internacional-em-relacao-a-novo-coronavirus&Itemid=812.
Yan, Y., Zou, Z., Sun, Y., Li, X., Xu, K. F., Wei, Y., ... & Jiang, C. (2013). Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell research, 23(2), 300-302.
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., ... & Tan, W. (2020). A novel coronavirus from patients with pneumonia in China, 2019. New England journal of medicine.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Vitor Hugo Santos da Silva; Adalgiza Deniele Veras Silva; Gabriel da Silva Duarte; Thasmyr das Mercês Gonçalves Corrêa; Francisco Daniel Queiroz Brito; Alessandra Ribeiro Moraes da Silva; José Eduardo Gomes Arruda
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
